Roberto De Luca

Roberto De Luca

Company: Philogen

Job title: Head of Therapeutic Antibodies


Should We Be Reconsidering Interferons? Discussing Antibody-Based Delivery of IFN-gamma for Cancer Therapy 10:00 am

Delve into why IFN has long been considered as a payload for antibodycytokine fusion proteins (immunocytokines) development, as high concentrations of this protein at the tumor site can mediate a potent influx and activation of leukocytes Learn how philogen’s previous works with IFN-based product suggest a possible competition between the antibody-mediated tumor targeting and the…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.